Last Updated on 21 July 2026

Is Sermorelin Safe? An Evidence-Based Safety Review

Written by Giselle Leung | Board-Certified Geriatric Pharmacist · Freelance Medical Writer & Medical Editor

PharmD, BCGP

Written by Giselle Leung | Board-Certified Geriatric Pharmacist · Freelance Medical Writer & Medical Editor

PharmD, BCGP

See Full Bio

Is sermorelin safe? While sermorelin appears reasonably well tolerated when used short-term, long-term safety data in adults remains limited. It is further complicated by the difficulty in getting this medication. Sermorelin is a synthetic 29-amino-acid fragment of growth hormone releasing hormone (GHRH), which signals the pituitary gland to release growth hormone (GH).1,2 It is available by prescription only in the United States and must be compounded by a pharmacy, because it is no longer commercially available on the market.3,4

The original branded sermorelin product, Geref, was approved only for pediatric growth hormone deficiency and was voluntarily discontinued in 2008 due to shrinking demand and manufacturing difficulties.5 Currently, adults use this medication off-label for anti-aging, performance, weight loss, or wellness goals.2 While studies show that using GHRH shows benefits in body composition and cognition,6 a clinical review in the Frontiers in Aging noted that data regarding the use of GHRH long-term is limited.7 Furthermore, use of sermorelin is controversial due to potential long-term side effects, such as increases in cardiovascular issues, development of type 2 diabetes, and increased cancer risk.7

Medical Disclaimer

This article is for general educational purposes only. It is not medical advice and is not a substitute for evaluation by a licensed clinician who can review personal health history, medications, and laboratory findings. Compounded medications, including sermorelin, are not FDA-approved finished products. Contraindications, drug interactions, and adverse effects exist with sermorelin, and individual risk varies. Readers should not start, stop, or change any prescription therapy based on information in this article. Decisions about sermorelin require an individualized assessment with a qualified prescribing clinician.

At a Glance

  • Short-term studies report sermorelin is generally well tolerated, but this is not the same as established long-term safety.
  • Common reported side effects include injection-site reactions, flushing, headache, nausea, dizziness, and rare allergic reactions.
  • Sermorelin is prescription only in the United States and all currently available sermorelin is compounded.
  • Compounded products are not FDA-approved, and “compounded” does not mean a medication is safe.
  • Sermorelin is on the World Anti-Doping Agency (WADA) prohibited list, and therapeutic-use exemptions are rarely granted.
  • Contraindications and cautions include active cancer, pregnancy and breastfeeding, uncontrolled thyroid disease, and significant liver or kidney impairment.
  • Products from online sources compounded without a prescription or marketed as “research chemicals” carry serious purity, dosing, and contamination risks.

How Sermorelin Works in the Body

Sermorelin is a GHRH analog that works by mimicking the body’s own GHRH signal. When injected, it binds receptors on the pituitary gland and prompts the release of stored growth hormone in a way that follows the pituitary gland’s normal regulatory checks.1,2 This differs from injecting recombinant human growth hormone (rhGH), which acts directly on receptors in the body’s tissues and bypasses pituitary gland control.

Since sermorelin acts directly on the pituitary gland, it is assumed that the body’s own feedback loops limit how much GH is released.2 Even though this may be true, a drug can act through a physiologic pathway and still cause unintended effects, especially with long-term use, in older adults, or in people with medical conditions that change hormone signaling.

According to the Endocrine Society, growth hormone therapy in adults is appropriate only for adult growth hormone deficiency that is confirmed with provocative testing, not for age-related changes in GH levels.8 This is important because GH naturally declines with age, and lower GH levels alone do not indicate disease or justify treatment.8,9

The pituitary gland’s response to sermorelin can also vary based on age, body composition, thyroid status, glucose handling, and other medications.2 Current studies are limited in defining whether sermorelin is safe or beneficial long-term. 

Common and Serious Sermorelin Side Effects

Reported side effects of sermorelin in short-term studies have generally been mild and self-limiting.2,6 The most frequently described include redness, pain, or swelling at the injection site, flushing, headache, nausea, dizziness, and rare allergic reactions.2,6,7 Other side effects include fluid retention (edema) and changes in fasting glucose or insulin sensitivity due to hormonal effects.7,9,10 Allergic reactions, while uncommon, can occur with any injected peptide.

Some patients report symptoms such as tingling, joint discomfort, or sleep changes, which may result from GH effects or unrelated factors. Serious adverse effects were uncommon in published short-term trials, but it does not reflect long-term safety.6,7,8 Patients who notice new or worsening symptoms, particularly signs of allergic reaction, persistent headache, vision changes, or new swelling, should contact their clinician.

Who Should Not Take Sermorelin: Contraindications and Cautions

Sermorelin is not appropriate for everyone. Contraindications and cautions include active malignancy, pregnancy, breastfeeding, hypersensitivity to the drug, and significant hypothalamic or pituitary disease that alters expected response.5,8 Caution must be taken in patients with the following conditions: uncontrolled thyroid disease, diabetes or prediabetes; and significant liver or kidney impairment.8,9,10 The same caution applies to younger adults whose hypothalamic-pituitary axis is functioning normally.8,9,10 Competitive athletes face an additional regulatory barrier with WADA.

A history of cancer warrants careful clinician review because growth hormone and insulin-like growth factor 1 (IGF-1) pathways interact with cell growth signaling, and the long-term effect of stimulating GH release in cancer survivors is not well established.9,11 Even though this is a precautionary concern rather than evidence of confirmed harm, most clinicians treat an active or recent malignancy as a strong reason to avoid somatotropic axis stimulation.8,11

Pregnancy and breastfeeding are contraindications because safety data in these populations does not exist. Any hormonal therapy without established fetal or infant safety should be avoided.5 Thyroid disease can alter the GH response, and uncontrolled diabetes raises concern because GH can reduce insulin sensitivity.9,10 Liver and kidney impairment may affect clearance and IGF-1 production.

For athletes, sermorelin appears on the WADA prohibited list as a GH-releasing factor.13 USADA additionally notes that therapeutic-use exemptions (TUEs) for sermorelin are highly unlikely outside narrow documented medical circumstances.14

What Compounded and Off-Label Mean for Sermorelin Safety

All sermorelin products currently available in the United States are compounded, which are prepared by a licensed pharmacy rather than manufactured by a pharmaceutical company.3,4 Compounded drugs are regulated, but they do not undergo the drug approval process or testing required for safety, efficacy, and manufacturing consistency as FDA-approved finished products.3 Instead, standards for quality depend on where the compounded drug is made.

Compounding pharmacies fall under two categories. Section 503A pharmacies prepare medications for individual patients based on a specific prescription, while 503B outsourcing facilities can produce larger batches under stricter federal oversight.3 Both operate under defined rules, but neither classification is equivalent to FDA approval of a finished drug product.

The only sermorelin product approved by the FDA was Geref, which was used for pediatric growth hormone deficiency. It was voluntarily discontinued in 2008 for commercial reasons rather than safety concerns.5 Current compounded sermorelin products are not the same as Geref and have not undergone equivalent FDA regulatory review.

Sermorelin is prescription only. Use of sermorelin for anti-aging, athletic performance, weight loss, or general wellness is off-label, meaning it is not an FDA-approved indication.4,8 Off-label prescribing is legal when clinically justified. However, it shifts more responsibility onto the prescribing clinician and patient to weigh limited evidence against potential risk.

What Long-Term Safety Data Actually Shows

Long-term safety data for sermorelin in healthy adults is limited. Most published studies are short, involve modest numbers of participants, and focus on pediatric growth hormone deficiency or short-term adult tolerability rather than the effects of chronic off-label use.6,8 In a systematic review of the trials completed with older adults, the effects of GH were limited, resulting in minor improvements in body composition and more side effects.9 As a result, use of GH in older adults should be used with caution. 

Although it is tempting to extrapolate from rhGH safety literature, sermorelin is different compared to rhGH. rhGH delivers exogenous growth hormone directly to tissues in the body and has documented risks including glucose intolerance, fluid retention, and concerns about IGF-1 elevation and possible cancer signaling in long-term use.10,12 Sermorelin, on the other hand, acts upstream through the pituitary gland, leading to a different exposure profile. Relevant long-term outcomes in adults using sermorelin off-label have not been characterized in large studies.6,9

Short-term tolerability does not equal long-term safety. This recurring confusion in marketing material requires one to look over the data about sermorelin carefully.

What to Consider

For readers weighing whether sermorelin is appropriate, one has to consider more than just the side effects. A responsible evaluation considers clinical indication, baseline testing, sourcing, monitoring, contraindications, and how evidence is being framed. The following criteria are not a recommendation to use sermorelin. Instead, they are a framework for a more informed conversation with a qualified clinician.

Criterion 1: Documented Clinical Indication

Symptoms, such as fatigue, reduced muscle tone, or sleep changes, are common and have many causes. They do not by themselves establish a clinical indication for GH-replacement therapy.8 To establish a documented clinical indication, the clinician must evaluate the patient for a defined diagnosis, establish a clinical rationale, and set up treatment goals that can be monitored over time. The Endocrine Society distinguishes adult growth hormone deficiency confirmed by provocative testing from age-related decline in GH levels, which is not an indication for treatment.8

Criterion 2: Baseline Laboratory Evaluation

Baseline laboratory testing may identify conditions that require further evaluation before starting treatment. The conditions of concern include abnormal glucose, thyroid dysfunction, or liver or kidney impairment.9,11 Testing does not by itself confirm that a treatment is appropriate or safe. No single laboratory marker is universally required. Instead, the clinician must utilize professional judgment. IGF-1 levels, fasting glucose, hemoglobin A1c, thyroid function, and basic metabolic panels are examples a clinician may consider, but the relevance of each depends on the individual patient.8,9,10

Criterion 3: Pharmacy Sourcing and Accreditation

Pharmacy quality standards matter but are not the only basis to establish clinical effectiveness or safety. A compounding pharmacy may be properly licensed, accredited by organizations such as the Pharmacy Compounding Accreditation Board, and compliant with 503A or 503B rules, yet accreditation does not transform a compounded preparation into an FDA-approved finished product.3 A valid prescription for sermorelin is a necessary requirement. Any source offering sermorelin without a prescription, marketing it as a “research chemical,” or selling it directly to consumers online should be considered a red flag for both legal and safety reasons.4,15

Criterion 4: Ongoing Monitoring and Follow-Up

When using sermorelin, patients must attend follow-up appointments at defined intervals to review symptoms, side effects, and relevant laboratory values.8 Monitoring allows for reassessment if expected goals are not met or if adverse effects occur. Discontinuation of sermorelin may be recommended by the clinician if benefits are unclear, side effects emerge, or new contraindications appear. Patients should be able to ask how progress will be measured and what would prompt the clinician to recommend stopping.

Criterion 5: Cancer History and Contraindications

A personal history of cancer, pregnancy, breastfeeding, or active endocrine disorders warrants careful review before any GHRH therapy.5,8,12 Theoretical concerns about GH and IGF-1 signaling in cancer biology are not the same as proven harm, but they are serious enough that to require thorough consultation with the clinician.7,12 Patients with these histories should expect their clinician to ask detailed questions and may reasonably be advised against sermorelin even if other criteria are met.

Criterion 6: Evidence and Risk Framing

Biologic theory, anecdotal reports, and rigorous long-term safety data are not equivalent to solid recommendations for use. Mechanism-based arguments about endogenous GH stimulation are not proof of safety, just as short-term tolerability studies are not proof of long-term safety.6,9 Evidence for using sermorelin off-label is currently limited and requires careful analysis of the current data available. A clinician who acknowledges uncertainty is being honest, not unhelpful.

What Happens After You Contact a Provider

A typical evaluation involves an intake questionnaire, medical history review, baseline laboratory testing where appropriate, and a consultation with the clinician.8 Based on this review, a clinician may or may not prescribe sermorelin. A legitimate provider may decline to prescribe if the clinical rationale is weak, contraindications exist, or expectations are unrealistic. Programs that guarantee a prescription before any evaluation, that skip laboratory work entirely, or that offer the drug without a documented prescription should be treated as red flags and to be avoided completely.

Conclusion

Is sermorelin safe? Short-term studies suggest sermorelin is generally well tolerated, but long-term safety data in adults using it off-label are limited. Sermorelin was previously FDA-approved for growth hormone deficiency in children with growth failure, but the branded product has been discontinued. Currently available compounded sermorelin products are not FDA-approved, although they may be dispensed by a licensed compounding pharmacy with a valid prescription. Athletes should be aware that sermorelin is prohibited under WADA rules.

You can reduce your risk of adverse effects from sermorelin by working with a licensed clinician and licensed and accredited compounding pharmacy.

Frequently Asked Questions

There is no established evidence that sermorelin causes cancer, but a theoretical concern exists because growth hormone and IGF-1 pathways interact with cell growth signaling.10,12 If you have a personal or strong family history of cancer, you should discuss this carefully with your clinician, who may advise against sermorelin. Long-term cancer-related outcomes in adults using sermorelin off-label have not been studied in large trials.6,10

For women who are not pregnant or breastfeeding, the short-term side-effect profile reported in studies appears generally similar to that in men, though sex-specific long-term data are limited.6 Pregnancy and breastfeeding are contraindications, because safety data in these situations do not exist.5 If you become pregnant, you should discuss contraception planning and risk with your clinician before starting.

If you stop sermorelin, your pituitary gland returns to its prior pattern of growth hormone release, and any symptomatic effects you noticed during treatment may gradually fade.2 There is no established withdrawal syndrome described in published literature for sermorelin. You should still tell your clinician before stopping so that any related medications, labs, or follow-up plans can be adjusted appropriately.

Sermorelin works upstream through the pituitary gland while recombinant human growth hormone (rhGH) delivers GH directly, and some clinicians argue this difference may produce a more regulated GH exposure.2,9 However, this is a mechanism-based argument, not a conclusion supported by long-term comparative safety trials in adults. You should not assume sermorelin is automatically safer simply because it acts through a more physiologic pathway.

Blood work helps identify conditions that change risk or interpretation, such as abnormal glucose, thyroid dysfunction, or liver or kidney issues.8,9 It provides a baseline for later comparison. Laboratory testing does not guarantee that treatment is appropriate or safe. If a program offers sermorelin without any baseline evaluation, you should view that as a significant warning sign.

Growth hormone can reduce insulin sensitivity, so sermorelin may affect glucose control in people with diabetes or prediabetes.9,11 If you have either condition, your clinician should review whether sermorelin is appropriate and how glucose will be monitored. You should not start sermorelin without discussing your diabetic history.

Sermorelin is a GHRH analog, while tesamorelin is a longer-acting GHRH analog approved for HIV-associated lipodystrophy.16,17 Ipamorelin is a different class of compound that acts on the ghrelin receptor, leading to the release of GH similar to GHRH itself.18,19 These compounds have different regulatory statuses, evidence bases, and side effect profiles. You should not assume their safety profiles are interchangeable. Ipamorelin currently lacks FDA-approved indications for any use, because it is an investigative drug.

No. Online sellers that sell “research chemicals” or sermorelin without a prescription operate outside legitimate pharmacy regulation, and their products may have unreliable purity, incorrect dosing, contamination, or no active ingredient at all.4,15 Buying injectable peptides this way carries serious health and legal risks. You should only obtain sermorelin using a licensed prescriber’s prescription and through a legitimate compounding pharmacy.

References

  1. Frohman LA, Jansson JO. Growth hormone-releasing hormone. Endocrine Reviews. 1986;7(3):223-253. 
  2. Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clinical Interventions in Aging. 2006;1(4):307-308. 
  3. Compounding and the FDA: Questions and Answers. U.S. Food and Drug Administration. Published September 16, 2025. Accessed June 4, 2026. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
  4. Human Drug Compounding. U.S. Food and Drug Administration. Published February 13, 2026. Accessed June 4, 2026. https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-compounding
  5. Determination That GEREF (Sermorelin Acetate) Injection, 0.5 Milligrams Base/Vial and 1.0 Milligrams Base/Vial, and GEREF (Sermorelin Acetate) Injection, 0.05 Milligrams Base/Amp, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness. [Documentation of a 2008 Discontinuation]. Federal Register. U.S. Food and Drug Administration. Published March 4, 2013. Accessed June 4, 2026. https://www.federalregister.gov/d/2013-04827
  6. Khorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab. 1997;82(5):1472-1479. doi:10.1210/jcem.82.5.3943
  7. Fernández-Garza LE, Guillen-Silva F, Sotelo-Ibarra MA, Domínguez-Mendoza AE, Barrera-Barrera SA, Barrera-Saldaña HA. Growth hormone and aging: a clinical review. Front Aging. 2025;6:1549453. 
  8. Molitch ME, Clemmons DR, Malozowski S, et al. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism. 2011;96(6):1587-1609. 
  9. Liu H, Bravata DM, Olkin I, et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Annals of Internal Medicine. 2007;146(2):104-115.
  10. Bartke A, Sun LY, Longo V. Somatotropic signaling: trade-offs between growth, reproductive development, and longevity. Physiological Reviews. 2013;93(2):571-598. 
  11. Møller N, Jørgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocrine Reviews. 2009;30(2):152-177. 
  12. Renehan AG, Zwahlen M, Egger M. Adiposity and cancer risk: new mechanistic insights from epidemiology. Nature Reviews Cancer. 2015;15(8):484-498. 
  13. Prohibited List. World Anti-Doping Agency. Published January 1, 2026. Accessed June 4, 2026. https://www.wada-ama.org/en/prohibited-list
  14. Growth Hormone in Sport: What Athletes Should Know. U.S. Anti-Doping Agency. Accessed June 4, 2026. https://www.usada.org/spirit-of-sport/education/growth-hormone-what-athletes-should-know/
  15. Warning letter to Xcel Research LLC. U.S. Food and Drug Administration. Published December 10, 2024. Accessed June 4, 2026. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/xcel-research-llc-694608-12102024
  16. Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine. 2007;357(23):2359-2370. 
  17. Sigalos JT, Pastuszak AW. The safety and efficacy of growth hormone secretagogues. Sexual Medicine Reviews. 2018;6(1):45-53.
  18. Definition of ipamorelin. National Cancer Institute. Accessed June 4, 2026. https://www.cancer.gov/publications/dictionaries/cancer-drug/def/ipamorelin
  19. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561.